Shilpa Medicare shares soar over 10% ahead of Q4 earnings; check company's latest update

The product is currently under development.

Under this agreement, Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa’s Recombinant Human Albumin in Europe. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments. Shilpa has been investing in the development of this novel product for about 8 years and has also set up a large-scale fermentation facility for the manufacture of recombinant human albumin to address market demand for this life-saving drug at a global scale.

"This collaboration marks a major milestone in Shilpa’s expansion into global biosimilar and biopharmaceutical markets, leveraging Orion’s strong regional presence, regulatory expertise, and well-established commercial infrastructure," Shilpa Medicare said.

“Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental & manufacturing capabilities to bring recombinant human albumin to market,” said Madhav Bhutada, Managing Director, Shilpa Biocare. “This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets," said Bhutada.

Recombinant human albumin is a key plasma protein used in various therapeutic applications and as a critical component in vaccine and biologics manufacturing.

Shilpa Medicare’s recombinant human albumin is developed using a robust non-human expression system ensuring high safety, scalability, and virus-free production, addressing key limitations associated with human-derived albumin, the company added.

About Shilpa Medicare Ltd.

Shilpa Medicare Ltd., headquartered in India, is a diversified pharmaceutical company engaged in the manufacture of complex generics, biologics, and active pharmaceutical ingredients (APIs).

Last seen, the stock was trading at ₹851.35 on the BSE, up 8.94%.